Sexual dysfunction with antihypertensive and antipsychotic agents

P. J. Smith, Robert Talbert

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

The physiology of the normal sexual response, epidemiology of sexual dysfunction, and the pharmacologic mechanisms involved in antihypertensive- and antipsychotic-induced problems with sexual function are discussed, with recommendations for patient management. The physiologic mechanisms involved in the normal sexual response include neurogenic, psychogenic, vascular, and hormonal factors that are coordinated by centers in the hypothalamus, limbic system, and cerebral cortex. Sexual dysfunction is frequently attributed to antihypertensive and antipsychotic agents and is a cause of noncompliance. Drug-induced effects include diminished libido, delayed orgasm, ejaculatory disturbances, gynecomastia, impotence, and priapism. The pharmacologic mechanisms proposed to account for these adverse effects include adrenergic inhibition, adrenergic-receptor blockade, anticholinergic properties, and endocrine and sedative effects. The most frequently reported adverse effect on sexual function with the antihypertensive agents is impotence. It is seen most often with methyldopa, guanethidine, clonidine, and propranolol. In contrast, the most common adverse effect on sexual function with the antipsychotic agents involves ejaculatory disturbances. Thioridazine, with its potent anticholinergic and α-blocking properties, is cited most often. Drug-induced sexual dysfunction may be alleviated by switching to agents with dissimilar mechanisms to alter the observed adverse effect while maintaining adequate control of the patient's disease state.

Original languageEnglish (US)
Pages (from-to)373-384
Number of pages12
JournalClinical Pharmacy
Volume5
Issue number5
StatePublished - 1986

Fingerprint

Antihypertensive Agents
Antipsychotic Agents
Cholinergic Antagonists
Erectile Dysfunction
Thioridazine
Priapism
Orgasm
Gynecomastia
Methyldopa
Guanethidine
Libido
Limbic System
Clonidine
Hypnotics and Sedatives
Propranolol
Pharmaceutical Preparations
Cerebral Cortex
Adrenergic Agents
Adrenergic Receptors
Hypothalamus

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Smith, P. J., & Talbert, R. (1986). Sexual dysfunction with antihypertensive and antipsychotic agents. Clinical Pharmacy, 5(5), 373-384.

Sexual dysfunction with antihypertensive and antipsychotic agents. / Smith, P. J.; Talbert, Robert.

In: Clinical Pharmacy, Vol. 5, No. 5, 1986, p. 373-384.

Research output: Contribution to journalArticle

Smith, PJ & Talbert, R 1986, 'Sexual dysfunction with antihypertensive and antipsychotic agents', Clinical Pharmacy, vol. 5, no. 5, pp. 373-384.
Smith, P. J. ; Talbert, Robert. / Sexual dysfunction with antihypertensive and antipsychotic agents. In: Clinical Pharmacy. 1986 ; Vol. 5, No. 5. pp. 373-384.
@article{fdbd51d04b1a41aea1dfad0a92f42684,
title = "Sexual dysfunction with antihypertensive and antipsychotic agents",
abstract = "The physiology of the normal sexual response, epidemiology of sexual dysfunction, and the pharmacologic mechanisms involved in antihypertensive- and antipsychotic-induced problems with sexual function are discussed, with recommendations for patient management. The physiologic mechanisms involved in the normal sexual response include neurogenic, psychogenic, vascular, and hormonal factors that are coordinated by centers in the hypothalamus, limbic system, and cerebral cortex. Sexual dysfunction is frequently attributed to antihypertensive and antipsychotic agents and is a cause of noncompliance. Drug-induced effects include diminished libido, delayed orgasm, ejaculatory disturbances, gynecomastia, impotence, and priapism. The pharmacologic mechanisms proposed to account for these adverse effects include adrenergic inhibition, adrenergic-receptor blockade, anticholinergic properties, and endocrine and sedative effects. The most frequently reported adverse effect on sexual function with the antihypertensive agents is impotence. It is seen most often with methyldopa, guanethidine, clonidine, and propranolol. In contrast, the most common adverse effect on sexual function with the antipsychotic agents involves ejaculatory disturbances. Thioridazine, with its potent anticholinergic and α-blocking properties, is cited most often. Drug-induced sexual dysfunction may be alleviated by switching to agents with dissimilar mechanisms to alter the observed adverse effect while maintaining adequate control of the patient's disease state.",
author = "Smith, {P. J.} and Robert Talbert",
year = "1986",
language = "English (US)",
volume = "5",
pages = "373--384",
journal = "Clinical Pharmacy",
issn = "0278-2677",
publisher = "American Society of Hospital Pharmacists",
number = "5",

}

TY - JOUR

T1 - Sexual dysfunction with antihypertensive and antipsychotic agents

AU - Smith, P. J.

AU - Talbert, Robert

PY - 1986

Y1 - 1986

N2 - The physiology of the normal sexual response, epidemiology of sexual dysfunction, and the pharmacologic mechanisms involved in antihypertensive- and antipsychotic-induced problems with sexual function are discussed, with recommendations for patient management. The physiologic mechanisms involved in the normal sexual response include neurogenic, psychogenic, vascular, and hormonal factors that are coordinated by centers in the hypothalamus, limbic system, and cerebral cortex. Sexual dysfunction is frequently attributed to antihypertensive and antipsychotic agents and is a cause of noncompliance. Drug-induced effects include diminished libido, delayed orgasm, ejaculatory disturbances, gynecomastia, impotence, and priapism. The pharmacologic mechanisms proposed to account for these adverse effects include adrenergic inhibition, adrenergic-receptor blockade, anticholinergic properties, and endocrine and sedative effects. The most frequently reported adverse effect on sexual function with the antihypertensive agents is impotence. It is seen most often with methyldopa, guanethidine, clonidine, and propranolol. In contrast, the most common adverse effect on sexual function with the antipsychotic agents involves ejaculatory disturbances. Thioridazine, with its potent anticholinergic and α-blocking properties, is cited most often. Drug-induced sexual dysfunction may be alleviated by switching to agents with dissimilar mechanisms to alter the observed adverse effect while maintaining adequate control of the patient's disease state.

AB - The physiology of the normal sexual response, epidemiology of sexual dysfunction, and the pharmacologic mechanisms involved in antihypertensive- and antipsychotic-induced problems with sexual function are discussed, with recommendations for patient management. The physiologic mechanisms involved in the normal sexual response include neurogenic, psychogenic, vascular, and hormonal factors that are coordinated by centers in the hypothalamus, limbic system, and cerebral cortex. Sexual dysfunction is frequently attributed to antihypertensive and antipsychotic agents and is a cause of noncompliance. Drug-induced effects include diminished libido, delayed orgasm, ejaculatory disturbances, gynecomastia, impotence, and priapism. The pharmacologic mechanisms proposed to account for these adverse effects include adrenergic inhibition, adrenergic-receptor blockade, anticholinergic properties, and endocrine and sedative effects. The most frequently reported adverse effect on sexual function with the antihypertensive agents is impotence. It is seen most often with methyldopa, guanethidine, clonidine, and propranolol. In contrast, the most common adverse effect on sexual function with the antipsychotic agents involves ejaculatory disturbances. Thioridazine, with its potent anticholinergic and α-blocking properties, is cited most often. Drug-induced sexual dysfunction may be alleviated by switching to agents with dissimilar mechanisms to alter the observed adverse effect while maintaining adequate control of the patient's disease state.

UR - http://www.scopus.com/inward/record.url?scp=0022513754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022513754&partnerID=8YFLogxK

M3 - Article

C2 - 2872991

AN - SCOPUS:0022513754

VL - 5

SP - 373

EP - 384

JO - Clinical Pharmacy

JF - Clinical Pharmacy

SN - 0278-2677

IS - 5

ER -